Inhibikase Therapeutics Inc (IKT) support and resistance · $215.2M cap
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
This page maps Inhibikase Therapeutics Inc (IKT) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
IKT currently screens at market cap $215.2M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new IKT 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the IKT quote page for the session range and the stock page for the full model.
Not investment advice.